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ARTICLE
β-amyloid and tau drive early Alzheimer’s disease
decline while glucose hypometabolism drives
late decline
Tyler C. Hammond1,2,11, Xin Xing1,3,11, Chris Wang3, David Ma1,4, Kwangsik Nho5, Paul K. Crane6, Fanny Elahi7,
David A. Ziegler 7, Gongbo Liang 3, Qiang Cheng8, Lucille M. Yanckello1,9, Nathan Jacobs 3 &
Ai-Ling Lin 1,2,9,10✉
Clinical trials focusing on therapeutic candidates that modify β-amyloid (Aβ) have repeatedly
failed to treat Alzheimer’s disease (AD), suggesting that Aβmay not be the optimal target for
treating AD. The evaluation of Aβ, tau, and neurodegenerative (A/T/N) biomarkers has been
proposed for classifying AD. However, it remains unclear whether disturbances in each arm
of the A/T/N framework contribute equally throughout the progression of AD. Here, using
the random forest machine learning method to analyze participants in the Alzheimer’s Dis-
ease Neuroimaging Initiative dataset, we show that A/T/N biomarkers show varying
importance in predicting AD development, with elevated biomarkers of Aβ and tau better
predicting early dementia status, and biomarkers of neurodegeneration, especially glucose
hypometabolism, better predicting later dementia status. Our results suggest that AD
treatments may also need to be disease stage-oriented with Aβ and tau as targets in early AD
and glucose metabolism as a target in later AD.
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A lzheimer’s disease (AD) is the most common form ofdementia worldwide and is defined biologically as thepathologic deposition of folded β-amyloid (Aβ) plaques,
and hyperphosphorylated neurofibrillary tau tangles in the brain
leading to neurodegeneration1–3. Clinically, AD presents as a
syndrome of progressive episodic memory and executive func-
tioning problems across a cognitive continuum ranging through
cognitively unimpaired (CU), mild cognitive impairment (MCI),
and AD. While there are currently five drugs approved by the
FDA to treat the symptoms of AD, there are no disease-
modifying therapies that alter the course of the disease. Over the
past few decades, the development of treatments for AD has been
largely focused on compounds which aim to reduce Aβ plaques,
either by directly targeting Aβ itself through antibodies or by
targeting the enzymes that cleave amyloid precursor protein
(APP) to produce it4,5. However, clinical trials of drugs targeting
Aβ had a 99.6% failure rate between 2002 and 20126, and two
more Aβ-focused drug trials failed in phase three in 20197. This
failure rate is among the highest of any disease area. The high
failure rate for AD drug candidates focused on Aβ indicates that
Aβ may not be the optimal therapeutic target to combat AD.
Careful analysis of AD biomarkers may give important insights
into underlying AD pathogenesis and clues about appropriate AD
treatments, since these biomarkers exist as proxies for AD neu-
ropathologic changes. Furthermore, an understanding of how the
biomarkers correlate with clinical symptoms of AD could inform
clinicians making AD management decisithe ons to improve
patient quality of life. The A/T/N biomarker framework pro-
mulgated by the National Institute on Aging-Alzheimer’s Asso-
ciation was created to be an unbiased classification scheme for the
three arms of biomarkers known to underlie AD pathology,
namely neuropathological loads of Aβ (A) and tau (T), and
neurodegeneration (N, including hypometabolism and brain
atrophy)8,9. Indeed, some research groups have demonstrated
that the distribution of tau tangles10 and hypometabolism (due to
low glucose uptake) are more strongly correlated with cognitive
performance than Aβ11. Moreover, brain atrophy is also sug-
gested to be highly correlated with AD progression12. However, it
remains unclear whether disturbances in each arm of the A/T/N
framework contribute equally to the progression of AD symp-
toms or if these factors instead have varying impacts at different
stages of AD progression. Understanding this stage-dependent
nature of the biomarkers could lead to important clues in pre-
venting and treating AD.
In order to determine the nature of the association of AD bio-
markers with the progression of AD symptoms, in this study, we
assessed the statistical importance of each arm of the A/T/N fra-
mework in predicting three progressive clinical statuses of cognitive
performance: cognitively unimpaired (CU), late mild cognitive
impairment (LMCI), and AD8. To do so, we used data from the
Alzheimer’s Disease Neuroimaging Initiatives (ADNI) database,
relating to four biomarkers: Aβ (assessed from 18Florbetapir-
positron emission tomography (PET)), phosphorylated tau
(pTau181, assessed from cerebrospinal fluid), glucose uptake
(assessed from 18fluorodeoxyglucose (FDG)-PET), and volumetric
measures (assessed from MRI). We used a random forest machine
learning algorithm to rank the importance of each biomarker in
predicting clinical dementia status. We chose the random forest
machine learning method because it not only has the ability to fit
models with high prediction accuracy due to its use of multiple
decision trees that combine to yield a consensus prediction, but also
is very interpretable due to its ranking capability of the relative
importance of predictors used in the classification (AD biomarkers
in our case). We also analyzed the relationship between A/T/N
biomarkers and memory composite and executive functioning
composite scores in order to assess more directly their association
with cognitive performance. We show that A/T/N biomarkers have
differing contributions in predicting clinical dementia status based
on the stage of cognitive impairment, with Aβ and pTau having
higher contribution in predicting early cognitive impairment (LMCI
vs. CU) and glucose uptake having higher contribution in pre-
dicting later cognitive impairment (AD vs. LMCI and AD vs. CU).
Our findings could help real-world patient populations by
informing clinicians to make AD management decisions according
to disease stage based on the expression of the relevant A/T/N
biomarkers, and by informing drug development teams to design
treatments to target the pathophysiology underlying the expression
of the biomarkers at the appropriate stage of disease progression.
Results
Participant characterizations and data selection. Participant
data was extracted from the ADNI database for inclusion in the
analysis. Participants were required to have baseline Aβ imaging
biomarkers (from 18Florbetapir PET), glucose uptake imaging
biomarkers (from 18FDG PET), brain volume imaging bio-
markers (from T1-weighted structural MRI), and cognitive test-
ing to be included in the analysis. Participants with three or more
missing values were excluded from the analysis. As tau imaging
was not available for most participants in the ADNI database, we
used a phosphorylated tau biomarker (pTau) from cerebrospinal
fluid (CSF) as a measure of tau levels. These criteria yielded a final
sample of 405 participants clinically diagnosed as being either
cognitively unimpaired (CU; n= 148) or with LMCI; (n= 147) or
Alzheimer’s disease (AD; n= 110) (Table 1).
The three study groups were balanced in terms of gender,
race, and ethnicity, but not age or education, across clinical
status, with the AD group being significantly older than LMCI
subjects and less educated than CU and LMCI subjects;
accordingly, we adjusted the features for age before applying
them to the random forest model since age is known to affect
brain volumetric measures. Notably, the groups differed in
terms of the expression of the ε4 allele of apolipoprotein E
(APOE ε4), the largest genetic risk factor for Alzheimer’s
disease13, and cognitive testing scores, with the AD group being
significantly more likely to carry APOE ε4 and to have lower
cognitive testing scores than CU and LMCI subjects. The
cognitive tests completed included the mini-mental state
examination, clinical dementia rating sum of boxes, Alzheimer’s
disease assessment scale-cognitive subscale (ADAS-cog 13),
composite memory score (ADNI_MEM), and composite execu-
tive functioning score (ADNI_EF). The biomarkers were further
stratified into 16 features classified according to the A/T/N
framework, comprising Aβ measures from six brain regions
(frontal lobe, cingulate gyrus, parietal lobe, temporal lobe,
precuneus, and hippocampus), glucose uptake (FDG) data from
three brain regions (angular gyrus, temporal lobe, and posterior
cingulum), volumetric measures from six regions (ventricles,
whole brain, entorhinal cortex, hippocampus, gray matter, and
white matter), and pTau levels from the CSF (Table 2). We show
the correlation of the 16 features with each other using a
heatmap (Supplementary Fig. 1). It shows that the Aβ measures
were highly correlated with each other, as were the FDG
measures, and the volumetric measures, while Aβ and pTau
were negatively correlated with FDG and volumetric measures.
Relative importance of AD biomarkers in early and late AD.
We first sought to determine the relative importance of each
biomarker feature in predicting clinical dementia status in three
participant group pairings: CU vs. LMCI, LMCI vs. AD, and CU
vs. AD. Table 3 shows the descending order ranking of the
relative importance of the 16 features in predicting clinical
ARTICLE COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-020-1079-x
2 COMMUNICATIONS BIOLOGY |           (2020) 3:352 | https://doi.org/10.1038/s42003-020-1079-x | www.nature.com/commsbio
dementia status based on the random forest method, a machine-
learning algorithm that utilizes multiple decision trees to classify
and rank variables according to their accuracy in predicting
outcomes. Notably, the top half (top 8) of the features made up
the majority of the relative importance (69.1, 75.45, and 86.74%)
for each cognitive state classification. In CU vs. LMCI, hippo-
campal volume ranked highest in relative prediction accuracy
with a relative importance of 12.69%, followed by four Aβ fea-
tures, pTau, FDG in the angular gyrus (FDG-Angular), and
entorhinal cortex volume; thus, features from all three arms of the
A/T/N framework were represented in the top eight features in
the CU vs. LMCI comparison. In contrast, in LMCI vs. AD,
neurodegeneration, i.e., the N component of the framework,
dominated the top eight features, with all three FDG glucose
uptake measurements (temporal lobe = 18.88% relative impor-
tance) and entorhinal cortex, hippocampal and ventricle volumes
represented. In particular, the three FDG features were ranked as
the top three contributors in the LMCI vs. AD comparison.
Moreover, the contribution of FDG was weighted even higher in
CU vs. AD, with FDG-Angular making up 23.78%, and FDG in
the posterior cingulum (FDG-CingulumPost) making up 16.99%
of the relative importance. Another N component, hippocampal
volume, also had an increased relative importance in the CU vs.
AD comparison relative to the other comparisons. The findings
suggest that, overall, Aβ and pTau are important contributors to
the progression from normal cognitive functioning to LMCI, but
that neurodegeneration, especially glucose hypometabolism,
emerges as a more important contributor when progressing from
LMCI to AD. Glucose hypometabolism also serves as a promi-
nent distinguishing feature between normal cognitive functioning
and AD. We replicated our analysis using the SHapley Additive
exPlanations (SHAP) technique and obtained a feature ranking
analysis consistent with those from the random forest analysis
(Supplementary Fig. 2).
Table 2 Biomarkers used in the feature analysis.
Data source Biomarker measure Features A/T/N classification
Positron emission tomography (PET) Amyloid-beta (AV45; 18Florbetapir) 1. Aβ-Frontal A
2. Aβ-Cingulate
3. Aβ-Parietal
4. Aβ-Temporal
5. Aβ-Precuneus
6. Aβ-Hippocampus
Glucose uptake (18FDG) 7. FDG-Angular N
8. FDG-Temporal
9. FDG-CingulumPost
Magnetic resonance imaging (MRI) Volumetric measures 10. Ventricle volume
11. Whole brain volume (WBV)
12. Entorhinal cortex volume
13. Hippocampal volume
14. Gray matter volume (GMV)
15. White matter volume (WMV)
Cerebrospinal fluid (CSF) phosphor-Tau (181P) 16. Phosphorylated tau (pTau) T
Amyloid-beta measures include Aβ from the frontal lobe (Aβ -Frontal), cingulate cortex (Aβ-Cingulate), parietal lobe (Aβ-Parietal), temporal lobe (Aβ -Temporal), precuneus (Aβ -Precuneus), and
hippocampus (Aβ -Hippocampus).
Glucose uptake measures include FDG from the angular gyrus (FDG-Angular), temporal lobe (FDG-Temporal), and posterior cingulum (FDG CingulumPost).
18FDG, Fluorodeoxyglucose.
Table 1 Demographic and cognitive data for the cross-sectional study population.
CU LMCI AD χ2-approx ε2 P-value
Subject characteristics
n 148 147 110
Age (years) 73.43 ± 6.29 71.98 ± 7.42 74.46 ± 8.39 7.207 0.0178 0.0272*
Gender (% Male) 51% 54% 60% 2.236 0.00554 0.3268
Education (years) 16.63 ± 2.53 16.70 ± 2.45 15.61 ± 2.55 13.395 0.0332 0.0012*
APOE ε4 carriers (%) 27% 57% 69% 53.653 0.133 <0.0001*
Ethnicity (% Hispanic) 5.4% 1.4% 3.6% 3.673 0.00909 0.1594
Race (% White) 89% 95% 92% 2.799 0.00693 0.2467
(% Black) 7% 3% 4%
(% Asian) 2% 1% 4%
Cognitive data
MMSE 29.06 ± 1.14 27.61 ± 1.82 23.14 ± 2.03 246.414 0.61 <0.0001*
CDRSB 0.03 ± 0.13 1.71 ± 1.00 4.60 ± 1.61 351.755 0.871 <0.0001*
ADAS-cog 13 9.08 ± 4.58 18.57 ± 7.08 30.16 ± 9.70 239.827 0.594 <0.0001*
ADNI_MEM 1.06 ± 0.63 −0.03 ± 0.66 −0.89 ± 0.54 266.260 0.63 <0.0001*
ADNI_EF 0.94 ± 0.81 0.16 ± 0.85 −0.83 ± 0.93 161.477 0.388 <0.0001*
Values are displayed as the mean ± SD. The χ2-approx test statistic is calculated from a Kruskal–Wallis test comparing the groups CU, LMCI, and AD. ε2 is the effect size calculated from a Kruskal–Wallis
test. Asterisk (*) next to P-value indicates statistical significance. DF= 2 for all comparisons.
CU, cognitively unimpaired; LMCI, late mild cognitive impairment; AD, Alzheimer’s disease; MMSE, mini-mental state examination; CDRSB, clinical dementia rating sum of boxes; ADAS-cog, Alzheimer’s
disease assessment scale-cognitive subscale; ADNI_MEM, composite memory score; ADNI_EF, composite executive functioning score.
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Accuracy of the top 8 features vs. all 16 features. We next
determined the prediction accuracy of all 16 features in classifying
the three participant group pairs. For all 16 features, accuracies of
73.17%, 71.01%, and 90.34% were obtained for the CU vs. LMCI,
LMCI vs. AD, and CU vs. AD comparisons, respectively (Table 4).
To ensure that our cognitive status classification model was robust,
the F1 score was also used to evaluate the precision and recall of the
model. The results show that the 16 features were able to classify the
three group pairs with high accuracy. Knowing that the top eight
biomarker features have high relative importance in predicting
cognitive status, we also explored whether the classification accu-
racy of the top eight features was comparable to that of all 16
features. Using the top eight features only, accuracies of 72.74%,
70.15%, and 91.63% were obtained for the CU vs. LMCI, LMCI vs.
AD, and CU vs. AD comparisons, respectively, thus confirming that
the accuracy of the top eight features was similar to that of all 16
features. Figure 1 depicts the comparison of the receiver operating
characteristic curves with five-fold cross validation14 between all 16
features and between the top 8 features. We found similar results in
accuracy when using three-fold and ten-fold cross validations for
comparison (Supplementary Table 1). The ROCs show that all 16
features performed slightly better than the top eight features in
distinguishing CU vs. LMCI and LMCI vs. AD. Precision recall
(PR) curves verified similar levels of accuracy (Supplementary
Fig. 3). These results suggest that there may be feature redundancy
present when all 16 features are used to predict cognitive state:
indeed, we found some of the features to be insignificant for cog-
nitive state classification, especially those with the lowest ranking.
Our findings suggest that the accuracy of the cognitive state pre-
diction model does not depend strictly on the number of features
used in the model, and that the top eight features may be sufficient
to accurately classify the three clinical cognitive statuses.
Correlation of AD biomarkers with cognitive performance. To
understand if the top eight features in classifying the three parti-
cipant group pairs are associated with performance on memory and
executive functioning tests, we performed a correlation analysis of
each feature on a memory composite score15 and on an executive
functioning composite score16. These composite scores are vali-
dated, psychometrically sophisticated composite scores based on the
ADNI battery of neuropsychological tests described above. Ranking
the biomarker features based on their r correlation value, we found
that the pattern of biomarker correlation with performance on
memory and executive functioning tests across participant groups
was similar to the pattern found in the feature ranking analysis.
When comparing the CU and LMCI groups (Fig. 2a), memory
performance was inversely correlated with Aβ biomarkers, espe-
cially Aβ in the temporal (Aβ-temporal), Aβ in the precuneus (Aβ-
precuneus), and Aβ in the frontal lobe (Aβ-frontal). Hippocampal
volume was also highly positively correlated and pTau was highly
negatively correlated with memory when comparing CU and LMCI.
However, when comparing LMCI and AD data (Fig. 2b), in all three
brain areas assessed, glucose uptake (FDG) was the feature most
highly positively correlated with memory, showing larger
Table 3 Ranking of each biomarker feature importance to prediction of diagnosis classification from the random forest analysis.
CU vs. LMCI LMCI vs. AD CU vs. AD
Rank Biomarker feature Relative
importance (%)
Biomarker feature Relative
importance (%)
Biomarker feature Relative
importance (%)
Top half 1 Hippocampus volume 12.69 FDG-temporal 18.88 FDG-angular 23.78
2 Aβ-frontal 11.51 FDG-angular 17.36 FDG-CingulumPost 16.99
3 Aβ-temporal 8.57 FDG-CingulumPost 12.11 Hippocampus volume 12.93
4 FDG-angular 8.32 Hippocampus volume 7.49 FDG-temporal 10.00
5 Entorhinal
cortex volume
7.88 Aβ-precuneus 5.14 Aβ-temporal 8.11
6 Aβ-precuneus 7.78 Aβ-temporal 4.97 Aβ-precuneus 6.20
7 pTau 7.60 pTau 4.82 Entorhinal
cortex volume
4.81
8 Aβ-cingulate 4.75 Entorhinal
cortex volume
4.76 pTau 3.92
Subtotal 69.1 75.45 86.74
Bottom half 9 Aβ-hippocampus 4.48 Aβ-parietal 4.71 Aβ-frontal 3.81
10 Ventricles 4.35 Aβ-frontal 3.98 Aβ-parietal 3.32
11 FDG-CingulumPost 4.29 Ventricles 3.69 Aβ-Hippocampus 3.17
12 GMV 4.20 Aβ-Hippocampus 3.14 Aβ-Cingulate 0.99
13 WMV 3.56 Aβ-Cingulate 2.63 Ventricles 0.65
14 FDG-temporal 3.48 GMV 2.59 GMV 0.60
15 WBV 3.45 WBV 2.46 WMV 0.38
16 Aβ-parietal 3.10 WMV 1.29 WBV 0.32
Subtotal 30.9 24.55 13.26
Sum 100 100 100
CU, cognitively unimpaired; LMCI, late mild cognitive impairment; AD, Alzheimer’s disease; FDG, fluorodeoxyglucose; GMV, gray matter volume; WMV, white matter volume; WBV, whole brain volume.
Table 4 Accuracy of all 16 features and of the top 8 features
in predicting diagnosis for each participant group
comparison.
All 16 features
CU vs. LMCI LMCI vs. AD CU vs. AD
Accuracy (%) 73.17 71.01 90.34
F1 score (%) 73.09 70.84 90.32
Top 8 features
CU vs. LMCI LMCI vs. AD CU vs. AD
Accuracy (%) 72.74 70.15 91.63
F1 score (%) 72.59 70.02 91.59
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correlation coefficients (r values) than those in the CU vs. LMCI
analysis. A similar correlation pattern was observed when com-
paring CU and AD data (Fig. 2c), with the correlation constants
being even larger for the FDG measurements than in the LMCI and
AD comparison. These results suggest that FDG biomarkers
become increasingly predictive of memory performance as cognitive
decline progresses from LMCI to AD. In particular, FDG-angular
appears to be an especially important predictor of memory func-
tion, as it has the highest correlation coefficient of the three FDG
biomarkers in these memory correlation analyses. A similar pattern
to that observed in the memory performance analyses emerged
when correlating executive functioning with the top eight bio-
markers with FDG biomarkers becoming increasingly predictive of
executive functioning as cognitive decline progresses (Fig. 3).
Notably, however, pTau and Aβ-Precuneus were more highly cor-
related with memory than executive functioning in the CU vs.
LMCI group (Figs. 2a and 3a). Interestingly, out of all the features,
pTau showed the smallest correlation with executive functioning in
each group (Fig. 3a–c).
Biomarker quantification for predicting LMCI and AD. Having
shown through ranking and correlation that the top eight features
from each participant group may be used as effective biomarkers
to predict disease progression from CU to LMCI and AD, we next
sought to assess the average values for each biomarker feature in
each diagnosis group that can be used for the clinical diagnosis of
these three cognitive statuses. Table 5 summarizes the values of
each of the top eight features that can be used to distinguish CU,
LMCI, and AD.
Discussion
We demonstrated three novel aspects in this study. First, we
employed AD biomarkers from all arms of the newly developed
A/T/N framework in a random forest machine learning analysis
powerful enough to accurately predict an AD diagnosis of CU,
LMCI, or AD and to rank biomarkers in order of their
importance in the prediction. Second, we showed that biomarkers
from the A/T/N framework have differing importance in pre-
dicting clinical dementia status across the disease progression,
with Aβ and pTau having higher importance in predicting early
cognitive impairment (CU vs. LMCI) and glucose uptake having
higher importance in predicting later cognitive impairment
(LMCI vs. AD and CU vs. AD) (Fig. 4). Our findings suggest that
Aβ and pTau accumulation contribute to the cognitive decline
that leads to LMCI, but may not be sufficient to lead to clinical
AD. Instead, neurodegeneration, especially in the form of glucose
hypometabolism, appears to be crucial for exacerbating cognitive
decline and furthering its progression to clinical AD. Addition-
ally, we found that Aβ and pTau are more strongly correlated
with cognitive performance in LMCI, while glucose hypometa-
bolism is more strongly correlated with cognitive performance in
AD, with FDG biomarkers becoming increasingly predictive of
memory and executive functioning as cognitive decline pro-
gresses. While others have previously documented the temporal
ordering of biomarkers preceding clinical symptomatology of
Alzheimer’s disease17, the real strength of our analysis is in
creating algorithms for computational analyses that are consistent
with available clinical and imaging data from data that has been
collected over many years. The challenge moving forward will be
to translate these algorithms into usable tools to that can assess
the capacity of patients in a clinically-friendly manner. Finally, we
demonstrated that the top eight features used in classifying the
three participant group pairs were just as accurate in predicting
clinical dementia status as all 16 features combined. The top eight
biomarker features that can be used to distinguish between stages
of cognitive impairment, which may prove useful for the future
prediction and diagnosis of LMCI and AD.
Machine learning techniques have previously been used to
predict cognitive status in AD using several separate bio-
markers, including those measured by FDG-PET18,19, structural
MRI18,20–22, amyloid-PET20,23,24, and CSF-phosphorylated
tau21,22. However, this is the first study to our knowledge to
combine biomarkers from all arms of the A/T/N framework
Fig. 1 Receiver operating characteristic (ROC) curves depicting the accuracy of all 16 biomarker features (top) vs. the top 8 biomarker features
(bottom). Comparison of receiver operating characteristic14 curves between all 16 biomarker features (top) and the top 8 biomarker features (bottom)
from the three diagnosis participant group comparisons: cognitively unimpaired (CU) vs. late mild cognitive impairment (LMCI), LCMI vs. Alzheimer’s
disease (AD), and CU vs. AD. Groundline refers to a model that cannot predict better than random chance. The mean ROC is calculated from the average
of the five ROC curves produced from the k-fold cross validation.
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Fig. 2 Correlation of top eight AD biomarkers with composite memory scores. Scatter plots showing the correlations of the top eight features with
performance on composite memory tests in each pairwise analysis among the cognitive statuses. (a) CU vs. LMCI. (b) LMCI vs. AD. (c) CU vs. AD. The
order of the scatter plots in each panel is according to the rank of the r correlation value when compared to composite memory score. The x-axis refers to
the indicated biomarker score and the y-axis refers to the composite memory score. Each dot refers to the indicated biomarker score and composite
memory score of a single participant.
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Fig. 3 Correlation of top eight AD biomarkers with executive functioning scores. Scatter plots showing the correlations of the top eight features with
performance on composite executive functioning tests in each pairwise analysis among the cognitive statuses (a) CU vs. LMCI. (b) LMCI vs. AD. (c) CU vs.
AD. The order of the scatter plots in each panel is according to the rank of the r correlation value when compared to composite executive functioning score.
The x-axis refers to the indicated biomarker score and the y-axis refers to the composite memory score. Each dot refers to the indicated biomarker score
and composite executive functioning score of a single participant.
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into one integrated analysis using a machine learning method
capable of classifying clinical dementia status and ranking the
biomarker features according to their relative importance in the
prediction model. Consistent with our findings, a previous
study showed that Aβ was more highly associated with cogni-
tive decline in cognitively normal participants, while glucose
hypometabolism was more closely linked with cognitive decline
in moderate and later stages of the disease (LMCI/AD)25.
Additionally, another study showed that FDG-PET, which
assesses glucose uptake, is more highly correlated to cognitive
ability than Aβ levels in patients with MCI and AD11. These
studies, in conjunction with our findings strongly support the
argument that cognitive decline in AD is initially propagated by
Aβ and tau aggregation but is further exacerbated by glucose
hypometabolism as cognitive decline progresses. Our findings
could better inform clinical AD management decisions and may
shift the targets of therapies to treat and prevent AD in future
drug development.
We found that Aβ and pTau accumulation are more highly
correlated with cognitive test scores in the CU vs. LMCI com-
parison than other biomarker features. In particular, Aβ deposi-
tion in the temporal cortex, precuneus, and frontal cortex, as well
as increased hippocampal volume, appear to be the most
important features in predicting memory and executive func-
tioning performance in early stage disease. Indeed, these areas
play a central role in a wide spectrum of highly integrated tasks
that are noticeably disturbed in patients with MCI. For example,
the temporal cortex is involved in memory, auditory cognition
and semantics26; the precuneus is involved in visuo-spatial image
processing and episodic memory retrieval27; the frontal lobe is
involved in executive function, attention, memory, and lan-
guage28; and the hippocampus is important for declarative
memory29. Additionally, we found that increased levels of pTau
were associated with memory performance but not executive
functioning in LMCI, which is consistent with previous find-
ings30. We note that some groups have found a high correlation
between tau levels and cognitive decline across the entire AD
spectrum31,32; even so, our results align with those of Mielke
et al., who found a significant association between tau and cog-
nitive performance in MCI, but a nonsignificant association
between these factors in AD33. We also noticed that the atrophy
of the hippocampus and entorhinal cortex (measures of neuro-
degeneration) were highly correlated in the CU vs. LMCI com-
parison of cognitive test scores; in addition to Aβ and pTau
burden, brain atrophy in these two regions may thus substantially
contribute to progression from CU to LMCI status, as other
groups have reported34.
We observed that impaired glucose uptake is most highly
correlated with cognitive test scores in LMCI vs. AD and CU vs.
AD groups. In particular, we found glucose uptake in the angular
gyrus (FDG-angular) to be the most important feature for pre-
dicting memory and executive functioning performance in later
Table 5 Average values of the top eight biomarker features for each diagnosis group that can be used to predict cognitive status.
Features CU LMCI AD A/T/N arm
Aβ-Precuneus (SUV cm−3) 0.0715 ± 0.0154 0.0873 ± 0.0231 0.107 ± 0.0272 A
Z= 5.79, P < 0.0001** r= 0.34 Z= 9.89, P < 0.0001ǂǂ r= 0.62
Aβ-Frontal (SUV cm−3) 0.00949 ± 0.00187 0.0114 ± 0.00260 0.0129 ± 0.00286
Z= 6.75, P < 0.0001** r= 0.39 Z= 9.07, P < 0.0001ǂǂ r= 0.56
Aβ-Cingulate (SUV cm−3) 0.0692 ± 0.00111 0.0787 ± 0.00181 0.0892 ± 0.00192
Z= 4.87, P < 0.0001** r= 0.28 Z= 8.03, P < 0.0001ǂǂ r= 0.50
Aβ-Temporal (SUV cm−3) 0.0259 ± 0.00523 0.0302 ± 0.00678 0.0331 ± 0.00672
Z= 6.76, P < 0.0001** r= 0.39 Z= 9.92, P < 0.0001ǂǂ r= 0.62
pTau (pg ml−1) 21.50 ± 8.87 29.70 ± 14.01 38.50 ± 16.52 T
Z= 5.62, P < 0.0001** r= 0.33 Z= 9.56, P < 0.0001ǂǂ r= 0.60
FDG-Angular (SUV cm−3) 1.21 ± 0.104 1.13 ± 0.149 0.956 ± 0.159 N
Z= 5.31, P < 0.0001** r= 0.31 Z= 11.46, P < 0.0001ǂǂ r= 0.71
FDG-CingulumPost (SUV cm−3) 3.03 ± 0.324 2.84 ± 0.391 2.47 ± 0.343
Z= 4.72, P < 0.0001** r= 0.27 Z= 10.69, P < 0.0001ǂǂ r= 0.67
FDG-Temporal (SUV cm−3) 8.24 ± 0.706 7.78 ± 0.983 6.73 ± 0.924
Z= 4.54, P < 0.0001** r= 0.26 Z= 10.82, P < 0.0001ǂǂ r= 0.67
Hippocampus volume (cm3) 7.49 ± 0.827 6.67 ± 1.11 5.91 ± 0.923
Z= 6.62, P < 0.0001** r= 0.39 Z=10.59, p < 0.0001ǂǂ r=0.66
Entorhinal cortex volume (cm3) 3.85 ± 0.587 3.39 ± 0.710 2.92 ± 0.622
Z= 5.51, P < 0.0001** r= 0.32 Z= 9.40, P < 0.0001ǂǂ r= 0.59
Values are displayed as the mean ± SD.
**P < 0.0001 calculated with a Wilcoxon rank-sum test comparing CU vs. LMCI.
ǂǂP < 0.0001 calculated with a Wilcoxon rank-sum test comparing CU vs. AD.
SUV is the standard uptake value, Z is the Z-score test statistic for Wilcoxon rank-sum test, r is the effect size for Wilcoxon rank-sum test.
Fig. 4 Relative importance of biomarkers predicting AD clinical
diagnosis. Diagram depicting the relative importance of biomarkers in
predicting AD clinical diagnosis (predictability). In early AD, Aβ and pTau
deposition in the brain have higher relative importance in predicting AD
clinical diagnosis. In late disease low glucose uptake in the brain has higher
relative importance in predicting AD clinical diagnosis.
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stages of AD, which is consistent with other groups who have
found reduced glucose uptake in the angular gyrus in later cog-
nitive decline35. This area is involved in semantic processing,
word comprehension, number processing, memory retrieval,
attention, spatial and social cognition, and reasoning36, all of
which are known to decline later in disease progression. Sustained
deficits in glucose uptake in key brain areas dramatically impair
cognitive functions by reducing proper support of neuronal
activity and functional processes37–39, and it is therefore unsur-
prising that we found that impaired glucose uptake is highly
correlated with advancing cognitive decline.
Notably, the individuals with AD that were included in the
current study were older and less educated than individuals in
other groups, and a higher percentage of AD patients carried the
APOE ε4 allele, the largest genetic risk factor for AD, than LMCI
and CU patients. Interestingly, all three of these factors are linked
to metabolic function40–44. A widely accepted cause of the
functional losses that accompany aging is decreased brain meta-
bolic function45,46. Indeed, mitochondrial function declines with
age in the brain and, thus, neural ATP production decreases,
which has been proposed to be a major factor in the aging-
associated loss of brain function40,43,46. Moreover, a recent study
demonstrated that regional brain metabolism and functional
connectivity as measured by fMRI differed with years of educa-
tion41: relative to less educated participants, highly educated
participants had higher glucose metabolism in the ventral areas of
the cerebrum, which are mainly involved in memory, language,
and neurogenesis, and functional connectivity experiments illu-
strated that the brains of the highly educated individuals were
overall more efficient and resilient to aging41. The APOE gene
plays a role in cholesterol and Aβ homeostasis39, and the APOE
ε4 allele is the strongest genetic risk factor for AD. Two recent
studies showed that disturbances in cholesterol metabolism, such
as alterations in bile acid metabolism, are highly associated with
AD47,48. Notably, the bile acid composition signatures were much
more highly associated with brain hypometabolism and atrophy
(i.e., the “N” component of the A/T/N framework) than with Aβ
and tau. Moreover, cross-sectional FDG-PET studies found that
cognitively unimpaired carriers of the APOE ε4 allele have
abnormally low glucose uptake in the same brain regions that
show hypometabolism in AD patients. Indeed, these metabolic
abnormalities were observed in late-middle-aged (40–60 years of
age) and young (20–39 years of age) APOE ε4 carriers, who had
intact memory and were free of Aβ or tau pathology49–53. These
neuroimaging results suggest that APOE ε4 carriers develop
functional brain abnormalities several decades before the possible
onset of dementia, and the results are in line with our finding that
a high percentage of those with clinical AD were APOE ε4
carriers.
There are many plausible reasons to explain why we found
glucose hypometabolism to be an important biomarker in pre-
dicting progressive cognitive decline in clinical AD. For example,
impairments in brain glucose metabolism are associated with
insulin resistance, which, in turn, exacerbates Aβ deposition39,54.
Indeed, AD is characterized by impaired brain insulin signaling55.
In line with this finding, type 2 diabetes mellitus, hyperlipidemia,
obesity, and other metabolic diseases increase the risk of devel-
oping AD12,39. Indeed the metabolic abnormalities present in AD
are often likened to a form of diabetes of the brain56. The pre-
servation of normal brain glucose metabolism is, thus, highly
associated with cognitive resilience. A recent study showed that
FDG-PET uptake in the bilateral anterior cingulate cortex and
anterior temporal pole was positively associated with global
cognition in cognitively unimpaired individuals over 80 years of
age, despite the fact that they were Aβ-positive and APOE ε4-
positive44. The results also suggest that normal cognitive
performance can be preserved even in the presence of Aβ and
APOE ε4 in 80+ year-old individuals. Another study using deep
learning methods showed that FDG-PET imaging can be used to
predict AD an average of 75.8 months prior to its final diagnosis
with 82% specificity and 100% sensitivity19.
Taken together, our current findings and those of previous
reports suggest that maintaining normal brain glucose metabo-
lism is critical for cognitive resilience; therefore, therapeutic
strategies for preventing or treating AD may need to shift focus
from Aβ toward the preservation and restoration of normal brain
metabolism. Interventions with this therapeutic strategy have
been reported that use intranasal insulin administration and a
ketogenic diet. Specifically, intranasal insulin therapy provides
rapid delivery of insulin to the central nervous system via bulk
flow along olfactory and trigeminal perivascular channels without
adversely affecting blood insulin or glucose levels and has been
shown to improve AD symptomology, although individual
patient responses may depend on gender, APOE genotype and
insulin formulation57–59. With regards to the potential benefits of
a ketogenic diet, ketone bodies can function as an alternative fuel
substrate in the brain when glucose is unavailable or when glu-
cose metabolism is impaired due to insulin resistance43,60–62. One
study showed that a ketogenic diet can modulate deposition of Aβ
and Tau in the CSF of MCI patients in conjunction with its
modulation of the gut microbiome and the production of short-
chain fatty acids63. This finding is consistent with an animal study
showing that a ketogenic diet enhanced Aβ clearance across the
blood-brain barrier and improved the composition of the gut
microbiome64. The gut microbiome produces secondary bile
acids, and, as mentioned above, alterations of bile acid production
have been observed in AD patients due to gut microbiome
imbalances, suggesting another mechanism by which AD patients
may benefit from therapeutic strategies aiming to restore normal
brain metabolism like the ketogenic diet47,48. Another animal
study showed that by modulating the gut microbiome with a
prebiotic diet, mice with the human APOE ε4 gene had enhanced
systemic metabolism and reduced neuroinflammatory gene
expression, another hallmark of AD pathology65. Collectively,
modulating metabolic function and the gut microbiome may have
a profound impact on reducing the risk of AD.
Future efforts should include the continued collection of the A/
T/N framework biomarkers to fill critical gaps in our under-
standing of how their expression is associated with AD and aging.
In our model construction and analysis, we used CSF-pTau to
fulfill the “T” component of the A/T/N framework9; however,
imaging-derived biomarkers provide information about the
location of the pathology in the brain that CSF-derived markers
do not8. Therefore, future work is needed to incorporate Tau-PET
imaging into the model66. In addition, glucose metabolism is
tightly coupled with cerebral blood flow (CBF)67,68, and neuro-
vascular dysfunction also plays a critical role in cognitive
impairment; thus, it will also be important to include CBF-MRI
measures in the future for a more thorough representation of AD
pathology. Indeed, Tau and CBF imaging data are currently
available for only a small subset of the ADNI cohort, and thus it
could not be incorporated into our model. Additionally, while the
available dataset from ADNI has more male participants, it
should be noted that AD disproportionately affects women69.
Future efforts may be needed to re-evaluate the outcome when
data from the female participants become more available.
In summary, we show that A/T/N biomarkers have cognitive
impairment stage-dependent roles in AD, with Aβ and pTau
better predicting LMCI and neurodegeneration (especially low
glucose uptake) better predicting clinical AD. Our findings may
partly explain the repeated failures of clinical trials attempting to
treat AD by modifying the Aβ load: it may be too late to gain
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therapeutic benefit from the treatment of Aβ when patients have
already progressed to the clinical AD stage. Therefore, our results
imply that treatments for AD may also need to be disease stage-
oriented: Aβ and tau may be appropriate targets early in the
disease course, but the restoration of brain glucose metabolism
should be explored as a treatment strategy for clinical AD. Our
findings may influence the thinking in the field regarding AD
progression and therapeutics.
Methods
Data pre-processing. Study data were obtained from the ADNI database, a long-
itudinal multicenter study designed to develop clinical, imaging, genetic, and bio-
chemical biomarkers for the early detection and tracking of Alzheimer’s disease.
Specifically, data were downloaded from the ADNI2 dataset within the ADNI data-
base since these data contained all the biomarkers of interest for the present study.
Specific details about the acquisition of the imaging measures have been reported
elsewhere70,71. Briefly, all subjects were consented under the approval of the IRB at
each testing site and scanned at 3 T for 3D T1-weighted volume, FLAIR, a long TE
gradient echo volumetric acquisition for micro hemorrhage detection, arterial spin-
labeling perfusion, resting state functional connectivity, and diffusion tensor imaging;
all enrolled subjects were also scanned for [18F]fluorodeoxyglucose PET (FDG-PET)
glucose uptake and [18F]florbetapir PET for amyloid imaging. The data were merged
from five subset datasets within the ADNI2 dataset to achieve a final dataset for
analysis consisting of demographic information, structural MRI volumes, FDG-PET
SUVs, amyloid-PET SUVs, white matter hyperintensities, and CSF-ptau measure-
ments. Age, gender, education, APOE ε4 carrier status, cognitive scores, and diagnosis
and the structural MRI variables of ventricle volume, whole brain volume, entorhinal
cortex volume, and hippocampal volume were extracted from the ADNIMERGE
subset dataset. FDG-angular, FDG-temporal, and FDG-CingulumPost were extracted
from the UC Berkeley FDG subset dataset. Aβ-frontal, Aβ-cingulate, Aβ-parietal, Aβ-
temporal, Aβ-precuneus, and Aβ-hippocampus were extracted from the UC Berkeley
AV45 subset dataset. Gray matter volume, white matter volume, and white matter
hyperintensity were extracted from the UC Davis white matter hyperintensity
volumes subset dataset. pTau concentration was extracted from the UPENN CSF
Biomarkers Elecsys subset dataset. Missing values were imputed by selecting the
twenty closest patients based on Euclidean distance with non-missing values in the
same group and averaging these values. Most of the missing values appeared in the
structural MRI data. Data imputation was performed on patients who had less than
three missing values. Patients with three or more missing values were deleted to avoid
bias caused by excessive imputation.
Machine learning analysis. The random forest (RF) classification algorithm was
used to assess the importance of all sixteen biomarker features in predicting the AD
clinical diagnosis, as determined by the progression of cognitive impairment as a
result of the disease process (CU, LMCI, or AD) (Table 2). The algorithm was
chosen, as opposed to other traditional statistical (e.g., ANOVA) and machine
learning methods, because (i) it is a robust classification method and (ii) it enables
feature ranking. An RF is trained by fitting multiple decision trees, each to a
different random subset of the examples and features of the full dataset. The
predictions of these decision trees are then combined to yield a single consensus
classification prediction. Given the trained RF, each feature is considered more
important if decision trees constructed from subsets that include the feature give
predictions that are more accurate. This is calculated by averaging the out-of-bag
accuracy (i.e., the accuracy on examples there were not used when training the tree)
of the individual decision trees that were trained using the corresponding feature.
We acknowledge that some of the features (e.g., brain volumetric measures) are
impacted with age; therefore, we adjusted the feature values for age accordingly.
Specifically, we used CU group dataset and performed a linear regression with the
seven brain volumetric measures used in our model as the feature variables and age
as the target regression variable. We applied the derived beta coefficients from the
regression model to the brain volumetric measures of the whole dataset and trained
these balanced brain volumetric measure values in our RF model. In the
implementation, we used the function sklearn.linear_model.LinearRegression of the
“scikit-learn” package to calculate the linear regression coefficients between brain
volumetric measures and age.
Figure 5a illustrates the workflow of the feature ranking and accuracy
performance using the random forest machine learning method. K-fold cross
validation (k= 5) was used to evaluate the performance of the RF classification
algorithm in predicting the AD clinical diagnosis. Using this strategy, the dataset
was randomly partitioned into five equal parts, and five RF models were trained,
each on a dataset consisting of four parts. Each of the trained RF models was
evaluated based on the prediction performance on the corresponding omitted
validation set. For evaluation, each complete data copy was forwarded into a
random forest classifier model utilizing the Python scikit-learn library v0.21.372. All
default parameters were used for the sklearn.ensemble.RandomForestClassifier
function, with the exception of the criterion parameter, where we used the entropy
option. Specifically, decision trees are classified in a binary fashion where the split
in the trees are from either true or false responses to feature thresholds. The
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Fig. 5 Flow chart of the random forest method used. a Flow chart depicting the analysis used with the random forest method. The AD biomarkers from
the original dataset were randomly split into five equal-sized subsets. For evaluation, each complete data copy was forwarded into a random forest
(decision tree; see b) classifier model. Final predictions were calculated and features were ranked based on the prediction of the majority of trees within
that training dataset. b Decision trees are classified in a binary fashion, where the split in the trees are from either true or false responses to feature
thresholds based on Gini Impurity. “Purity” is a measure homogeneity, with “0” as maximal purity, and “1” as maximal impurity.
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RandomForestClassifier decides the thresholds based on Gini Impurity. “Purity” is a
measure as to how homogenous the samples are, with “0” as maximal purity, and
“1” as maximal impurity. As the decision tree progresses down, the Gini values
eventually decrease to 0 (Fig. 5b). Final predictions were calculated and features
were ranked based on the prediction of the majority of trees within that training
dataset. The resulting predictions were evaluated on their ability to correctly
predict the AD clinical diagnosis in the validation dataset.
The cross-validated model prediction accuracy, receiver operating characteristic
curve (ROC) and F1 score were used to assess model performance.
The accuracy is calculated with the following Eq. (1):
Accuracy ¼ TPþ TN
TPþ TNþ FPþ FN ; ð1Þ
where TP is the true positives, TN the true negatives, FP the false positives, and FN
the false negatives.
The F1 score is calculated by the following Eq. (2):
F1 ¼ 2 
precision  recall
precisionþ recall ð2Þ
where precision is TP/(TP+ FP) and recall is TP/(TP+ FN). ROC curves compare
the true positive rate and false positive rate at different decision thresholds and are
often used to judge the performance of binary classifiers. F1 scores combine
precision and recall and are often used to evaluate models on imbalanced dataset,
since it is possible to obtain high accuracy on imbalanced datasets simply by
predicting the most common class. A high F1 score indicates low false positives and
low false negatives.
Statistics and reproducibility. In the Table 1, the overall dataset was initially
evaluated for group differences in age, gender, education, APOE genotype, ethnicity,
race, and cognitive test differences using non-parametric Kruskal–Wallis tests com-
paring the groups CU, LMCI, and AD using JMP 1.4 software. χ2-approximate values
and P-values were documented to identify statistical significance. ε2 values for effect
sizes were calculated using the “rcompanion” package in R statistical software.
To verify the reproducibility of five-fold validation used in the RF analysis, we
compared the results of accuracy and F1 score from those using three-fold and ten-
fold cross validations (Supplementary Table 1).
To verify the accuracy measurements validated using ROC, we also performed
precision recall (PR) curves calculation (Supplementary Fig. 3). Precision-recall
curve is another method to evaluate classification models, especially binary
classification models where the dataset is imbalanced. The average of precision
(AP) is calculated to determine the average precision score under different possible
thresholds. We used the scikit learn package sklearn.model_selection.
RandomizedSearchCV for hyperparameters optimization. The hyperparameters of
the RF model is as follows: “n_estimators”=3600, “min_samples_split”=5,
“min_samples_leaf”=8, “max_features”=“auto”, “max_depth”=50, and
“bootstrap”=False.
We also used the SHapley Additive exPlanations (SHAP) technique to
implement an additional feature ranking analysis. In our experiments, we applied
the SHAP on Random Forest Classifier. Using the SHAP method as a reference for
feature ranking analysis, the results showed similar feature importance ranking as
RF (Supplementary Fig. 2).
Gradient tree boosting (GTB), another classification method from the scikit-
learn package, was used as a comparison for the RF classification method
(Supplementary Table 2). The same tree estimators from the RF method were used
for GTB with all other default function parameters. The accuracies for the GTB
method were similar to the RF method. The accuracy of the GTB classifiers were
72.30%, 71.26%, and 91.87%, respectively for CU vs. LMCI, LMCI vs. AD, and CU
vs. AD clinical diagnosis. The model was also trained with 3- and 10-fold cross
validation for comparison. There were minor difference in the feature rankings
estimated using the GTB model as compared to the RF model but the same general
patterns hold true: Aβ and pTau are important contributors to the prediction of
early AD decline, but neurodegeneration, especially glucose hypometabolism, is a
more important predictor of later AD decline.
Pearson correlation analysis of cognitive performance. Pearson correlation was
used to evaluate linear relationships between individual biomarker features and
cognitive function using the JMP 1.4 software (Figs. 2 and 3). Pearson correlation
coefficient is calculated by the covariance of two variables over the product of their
standard deviation. The value range of Pearson correlation coefficient is from −1 to
1 with a higher absolute value indicating a stronger association and the sign
indicating a positive or negative association between the two variables.
Calculation of biomarker values. In the Table 5, biomarker values were calculated
for the different diagnosis groups and compared using two-sided Wilcoxon rank-sum
tests. Z-score test statistics were calculated using JMP 1.4 software and effect sizes r
were calculated with r (=Z/(√Nobs)). Amyloid standard uptake values (SUVs) were
intensity normalized to the whole cerebellum and volume was normalized by dividing
by the region of interest (ROI) in cubic centimeters (cm3). FDG SUVs were
normalized according to metaROIs described elsewhere73. Briefly, a set of pre-defined
regions of interest (FDG-ROIs) were developed by identifying regions cited frequently
in FDG-PET studies of AD and MCI patients. All coordinates of significant voxels
were transformed into MNI space. Intensity values were generated for coordinates
that reflected a combination of the Z-scores associated with the coordinate. The
volumes were intensity normalized using the maximum value, and volume was
normalized by dividing by the ROI in cubic centimeters (cm3).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The datasets analyzed during the current study are available in the Alzheimer’s Disease
Neuroimaging Initiative (ADNI) repository, http://adni.loni.usc.edu/.
Code availability
The code used in analysis for the current study are available in a GitHub control
repository, https://github.com/linbrainlab/machinelearning.git.
Received: 27 December 2019; Accepted: 15 June 2020;
References
1. Kumar, A., Singh, A. & Ekavali A review on Alzheimer’s disease
pathophysiology and its management: an update. Pharm. Rep. 67, 195–203
(2015).
2. Lane, C. A., Hardy, J. & Schott, J. M. Alzheimer’s disease. Eur. J. Neurol. 25,
59–70 (2018).
3. Sery, O., Povova, J., Misek, I., Pesak, L. & Janout, V. Molecular mechanisms of
neuropathological changes in Alzheimer’s disease: a review. Folia Neuropathol.
51, 1–9 (2013).
4. Modrego, P. & Lobo, A. A good marker does not mean a good target for
clinical trials in Alzheimer’s disease: the amyloid hypothesis questioned.
Neurodegener. Dis. Manage. 9, 119–121 (2019).
5. Briggs, R., Kennelly, S. P. & O’Neill, D. Drug treatments in Alzheimer’s
disease. Clin. Med. 16, 247–253 (2016).
6. Cummings, J. L., Morstorf, T. & Zhong, K. Alzheimer’s disease drug-
development pipeline: few candidates, frequent failures. Alzheimers Res. Ther.
6, 37 (2014).
7. Cummings, J., Lee, G., Ritter, A., Sabbagh, M. & Zhong, K. Alzheimer’s disease
drug development pipeline: 2019. Alzheimers Dement. 5, 272–293 (2019).
8. Jack, C. R. Jr. et al. NIA-AA research framework: toward a biological definition
of Alzheimer’s disease. Alzheimers Dement. 14, 535–562 (2018).
9. Jack, C. R. Jr. et al. A/T/N: an unbiased descriptive classification scheme for
Alzheimer disease biomarkers. Neurology 87, 539–547 (2016).
10. Josephs, K. A. et al. Tau aggregation influences cognition and hippocampal
atrophy in the absence of beta-amyloid: a clinico-imaging-pathological study
of primary age-related tauopathy (PART). Acta Neuropathol. 133, 705–715
(2017).
11. Jagust, W. J. et al. Relationships between biomarkers in aging and dementia.
Neurology 73, 1193–1199 (2009).
12. Zhang, Y. & Liu, S. Analysis of structural brain MRI and multi-parameter
classification for Alzheimer’s disease. Biomed. Tech. 63, 427–437
(2018).
13. Ward, A. et al. Prevalence of apolipoprotein E4 genotype and homozygotes
(APOE e4/4) among patients diagnosed with Alzheimer’s disease: a systematic
review and meta-analysis. Neuroepidemiology 38, 1–17 (2012).
14. McDonald, D. et al. An improved Greengenes taxonomy with explicit ranks
for ecological and evolutionary analyses of bacteria and archaea. ISME J. 6,
610–618 (2012).
15. Crane, P. K. et al. Development and assessment of a composite score for
memory in the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Brain
Imaging Behav. 6, 502–516 (2012).
16. Gibbons, L. E. et al. A composite score for executive functioning, validated in
Alzheimer’s Disease Neuroimaging Initiative (ADNI) participants with
baseline mild cognitive impairment. Brain Imaging Behav. 6, 517–527 (2012).
17. Jack, C. R. et al. Tracking pathophysiological processes in Alzheimer’s disease:
an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 12,
207–216 (2013).
18. Lu, D. et al. Multimodal and multiscale deep neural networks for the early
diagnosis of Alzheimer’s disease using structural MR and FDG-PET images.
Sci. Rep. 8, 5697 (2018).
COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-020-1079-x ARTICLE
COMMUNICATIONS BIOLOGY |           (2020) 3:352 | https://doi.org/10.1038/s42003-020-1079-x | www.nature.com/commsbio 11
19. Ding, Y. et al. A deep learning model to predict a diagnosis of Alzheimer
disease by using (18)F-FDG PET of the brain. Radiology 290, 456–464 (2019).
20. Trzepacz, P. T. et al. Comparison of neuroimaging modalities for the
prediction of conversion from mild cognitive impairment to Alzheimer’s
dementia. Neurobiol. Aging 35, 143–151 (2014).
21. Dong, A. et al. Heterogeneity of neuroanatomical patterns in prodromal
Alzheimer’s disease: links to cognition, progression and biomarkers. Brain
140, 735–747 (2017).
22. Wang, Y. et al. Diagnosis and prognosis of Alzheimer’s disease using brain
morphometry and white matter connectomes. Neuroimage Clin. 23, 101859
(2019).
23. Vlassenko, A. G., Benzinger, T. L. & Morris, J. C. PET amyloid-beta imaging
in preclinical Alzheimer’s disease. Biochim Biophys. Acta 1822, 370–379
(2012).
24. Mathotaarachchi, S. et al. Identifying incipient dementia individuals using
machine learning and amyloid imaging. Neurobiol. Aging 59, 80–90 (2017).
25. Landau, S. M. et al. Amyloid deposition, hypometabolism, and longitudinal
cognitive decline. Ann. Neurol. 72, 578–586 (2012).
26. Jackson, R. L., Bajada, C. J., Rice, G. E., Cloutman, L. L. & Lambon Ralph, M.
A. An emergent functional parcellation of the temporal cortex. NeuroImage
170, 385–399 (2018).
27. Cavanna, A. E. & Trimble, M. R. The precuneus: a review of its functional
anatomy and behavioural correlates. Brain 129, 564–583 (2006).
28. Chayer, C. & Freedman, M. Frontal lobe functions. Curr. Neurol. Neurosci.
Rep. 1, 547–552 (2001).
29. Opitz, B. Memory function and the hippocampus. Front. Neurol. Neurosci. 34,
51–59 (2014).
30. Sperling, R. A. et al. The impact of amyloid-beta and tau on prospective
cognitive decline in older individuals. Ann. Neurol. 85, 181–193 (2019).
31. Bejanin, A. et al. Tau pathology and neurodegeneration contribute to cognitive
impairment in Alzheimer’s disease. Brain 140, 3286–3300 (2017).
32. Huber, C. M., Yee, C., May, T., Dhanala, A. & Mitchell, C. S. Cognitive decline
in preclinical Alzheimer’s disease: amyloid-beta versus tauopathy. J.
Alzheimers Dis. 61, 265–281 (2018).
33. Mielke, M. M. et al. Association of plasma total tau level with cognitive decline
and risk of mild cognitive impairment or dementia in the mayo clinic study on
aging. JAMA Neurol. 74, 1073–1080 (2017).
34. Risacher, S. L. et al. Alzheimer disease brain atrophy subtypes are associated
with cognition and rate of decline. Neurology 89, 2176–2186 (2017).
35. Jeong, H. S., Park, J. S., Song, I. U., Chung, Y. A. & Rhie, S. J. Changes in
cognitive function and brain glucose metabolism in elderly women with
subjective memory impairment: a 24-month prospective pilot study. Acta
Neurol. Scand. 135, 108–114 (2017).
36. Seghier, M. L. The angular gyrus: multiple functions and multiple
subdivisions. Neuroscientist 19, 43–61 (2013).
37. Mergenthaler, P., Lindauer, U., Dienel, G. A. & Meisel, A. Sugar for the brain:
the role of glucose in physiological and pathological brain function. Trends
Neurosci. 36, 587–597 (2013).
38. Lin, A. L., Coman, D., Jiang, L., Rothman, D. L. & Hyder, F. Caloric restriction
impedes age-related decline of mitochondrial function and neuronal activity. J.
Cereb. Blood Flow Metab. 34, 1440–1443 (2014).
39. Neth, B. J. & Craft, S. Insulin resistance and Alzheimer’s disease: bioenergetic
linkages. Front. Aging Neurosci. 9, 345 (2017).
40. Kakimoto, A. et al. Age-related sex-specific changes in brain metabolism and
morphology. J. Nucl. Med. 57, 221–225 (2016).
41. Kim, J., Chey, J., Kim, S. E. & Kim, H. The effect of education on regional
brain metabolism and its functional connectivity in an aged population
utilizing positron emission tomography. Neurosci. Res. 94, 50–61 (2015).
42. Wu, L., Zhang, X. & Zhao, L. Human ApoE isoforms differentially modulate
brain glucose and ketone body metabolism: implications for Alzheimer’s disease
risk reduction and early intervention. J. Neurosci. 38, 6665–6681 (2018).
43. Riedel, B. C., Thompson, P. M. & Brinton, R. D. Age, APOE and sex: triad of
risk of Alzheimer’s disease. J. Steroid Biochem. Mol. Biol. 160, 134–147 (2016).
44. Arenaza-Urquijo, E. M. et al. The metabolic brain signature of cognitive
resilience in the 80+: beyond Alzheimer pathologies. Brain 142, 1134–1147
(2019).
45. Bentourkia, M. et al. Comparison of regional cerebral blood flow and glucose
metabolism in the normal brain: effect of aging. J. Neurol. Sci. 181, 19–28
(2000).
46. Wallace, D. C. A mitochondrial paradigm of metabolic and degenerative
diseases, aging, and cancer: a dawn for evolutionary medicine. Annu. Rev.
Genet. 39, 359–407 (2005).
47. MahmoudianDehkordi, S. et al. Altered bile acid profile associates with
cognitive impairment in Alzheimer’s disease—an emerging role for gut
microbiome. Alzheimers Dement. 15, 76–92 (2019).
48. Nho, K. et al. Altered bile acid profile in mild cognitive impairment and
Alzheimer’s disease: relationship to neuroimaging and CSF biomarkers.
Alzheimers Dement. 15, 232–244 (2019).
49. Thambisetty, M., Beason-Held, L., An, Y., Kraut, M. A. & Resnick, S. M.
APOE epsilon4 genotype and longitudinal changes in cerebral blood flow in
normal aging. Arch. Neurol. 67, 93–98 (2010).
50. Reiman, E. M. et al. Correlations between apolipoprotein E epsilon4 gene dose
and brain-imaging measurements of regional hypometabolism. Proc. Natl
Acad. Sci. USA 102, 8299–8302 (2005).
51. Reiman, E. M. et al. Declining brain activity in cognitively normal
apolipoprotein E epsilon 4 heterozygotes: a foundation for using positron
emission tomography to efficiently test treatments to prevent Alzheimer’s
disease. Proc. Natl Acad. Sci. USA 98, 3334–3339 (2001).
52. Fleisher, A. S. et al. Apolipoprotein E epsilon4 and age effects on florbetapir
positron emission tomography in healthy aging and Alzheimer disease.
Neurobiol. Aging 34, 1–12 (2013).
53. Reiman, E. M. et al. Functional brain abnormalities in young adults at genetic
risk for late-onset Alzheimer’s dementia. Proc. Natl Acad. Sci. USA 101,
284–289 (2004).
54. Wakabayashi, T. et al. Differential effects of diet- and genetically-induced
brain insulin resistance on amyloid pathology in a mouse model of
Alzheimer’s disease. Mol. Neurodegener. 14, 15 (2019).
55. Craft, S. et al. Cerebrospinal fluid and plasma insulin levels in Alzheimer’s
disease: relationship to severity of dementia and apolipoprotein E genotype.
Neurology 50, 164–168 (1998).
56. Rorbach-Dolata, A. & Piwowar, A. Neurometabolic evidence supporting the
hypothesis of increased incidence of type 3 diabetes mellitus in the 21st
century. Biomed. Res. Int. 2019, 1435276 (2019).
57. Craft, S. et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild
cognitive impairment: a pilot clinical trial. Arch. Neurol. 69, 29–38 (2012).
58. de la Monte, S. M. Early intranasal insulin therapy halts progression of
neurodegeneration: progress in Alzheimer’s disease therapeutics. Aging Health
8, 61–64 (2012).
59. Chapman, C. D., Schioth, H. B., Grillo, C. A. & Benedict, C. Intranasal insulin
in Alzheimer’s disease: food for thought. Neuropharmacology 136, 196–201
(2018).
60. Wang, Y. & Brinton, R. D. Triad of risk for late onset Alzheimer’s:
mitochondrial haplotype, APOE genotype and chromosomal sex. Front. Aging
Neurosci. 8, 232 (2016).
61. Lin, A. L., Zhang, W., Gao, X. & Watts, L. Caloric restriction increases ketone
bodies metabolism and preserves blood flow in aging brain. Neurobiol. Aging
36, 2296–2303 (2015).
62. Zhang, Y. et al. Ketosis proportionately spares glucose utilization in brain. J.
Cereb. Blood Flow Metab. 33, 1307–1311 (2013).
63. Nagpal, R., Neth, B. J., Wang, S., Craft, S. & Yadav, H. Modified
Mediterranean-ketogenic diet modulates gut microbiome and short-chain
fatty acids in association with Alzheimer’s disease markers in subjects with
mild cognitive impairment. EBioMed. 47, 529–542 (2019).
64. Ma, D. et al. Ketogenic diet enhances neurovascular function with altered gut
microbiome in young healthy mice. Sci. Rep. 8, 6670 (2018).
65. Hoffman, J. D. et al. Dietary inulin alters the gut microbiome, enhances
systemic metabolism and reduces neuroinflammation in an APOE4 mouse
model. PLoS One 14, e0221828 (2019).
66. Xia, C. et al. Association of in vivo [18F]AV-1451 Tau PET imaging results
with cortical atrophy and symptoms in typical and atypical Alzheimer disease.
JAMA Neurol. 74, 427–436 (2017).
67. Fox, P. T., Raichle, M. E., Mintun, M. A. & Dence, C. Nonoxidative glucose
consumption during focal physiologic neural activity. Science 241, 462–464
(1988).
68. Lin, A. L., Fox, P. T., Hardies, J., Duong, T. Q. & Gao, J. H. Nonlinear coupling
between cerebral blood flow, oxygen consumption, and ATP production in
human visual cortex. Proc. Natl Acad. Sci. USA 107, 8446–8451 (2010).
69. Pike, C. J. Sex and the development of Alzheimer’s disease. J. Neurosci. Res. 95,
671–680 (2017).
70. Jack, C. R. et al. Update on the magnetic resonance imaging core of the
Alzheimer’s disease neuroimaging initiative. Alzheimer’s Dement. 6, 212–220
(2010).
71. Jagust, W. J. et al. The Alzheimer’s disease neuroimaging initiative positron
emission tomography core. Alzheimer’s Dement. 6, 221–229 (2010).
72. van der Walt, S. et al. scikit-image: image processing in Python. PeerJ 2, e453
(2014).
73. Landau, S. M. et al. Associations between cognitive, functional, and FDG-
PET measures of decline in AD and MCI. Neurobiol. Aging 32, 1207–1218
(2011).
Acknowledgements
Data used in preparation of this article were obtained from the Alzheimer’s Disease Neu-
roimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within
the ADNI contributed to the design and implementation of ADNI and/or provided data but
did not participate in analysis or writing of this report. A complete listing of ADNI
ARTICLE COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-020-1079-x
12 COMMUNICATIONS BIOLOGY |           (2020) 3:352 | https://doi.org/10.1038/s42003-020-1079-x | www.nature.com/commsbio
investigators can be found at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/
ADNI_Acknowledgement_List.pdf Data collection and sharing for this project was funded
by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (National Institutes of Health
Grant U01 AG024904) and DOD ADNI (Department of Defense award number
W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National
Institute of Biomedical Imaging and Bioengineering, and through generous contributions
from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foun-
dation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir,
Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun;
F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE
Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research and Development,
LLC.; Johnson and Johnson Pharmaceutical Research and Development LLC.; Lumosity;
Lundbeck; Merck and Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neu-
rotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging;
Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian
Institutes of Health Research is providing funds to support ADNI clinical sites in Canada.
Private sector contributions are facilitated by the Foundation for the National Institutes of
Health (www.fnih.org). The grantee organization is the Northern California Institute for
Research and Education, and the study is coordinated by the Alzheimer’s Therapeutic
Research Institute at the University of Southern California. ADNI data are disseminated by
the Laboratory for Neuro Imaging at the University of Southern California. We also thank
Dr. Erin Abner of University of the Kentucky for statistical support and Mr. Thomas Dolan
of the University of Kentucky for graphical design. This research was supported by NIH
grants R01AG054459 and RF1AG062480 to A.-L.L., R03AG063250, R03AG054936, and
R01 LM012535 to K.N., ADNI Psychometrics R01AG029672 to P.K.C., training grant
T32DK007778 to L.M.Y., and NSF CAREER award (IIS #1553116) to N.J. This study is also
a part of the collaboration from the Friday Harbor Psychometrics Conference sponsored by
R13AG030995 (PI: Mungas).
Author contributions
T.C.H., X.X., D.M., K.N., P.K.C., F.E., D.A.Z., Q.C., and A.-L.L. participated in study
design. T.C.H., X.X., C.W., D.M., K.N., and A.-L.L. participated in ADNI data identifi-
cation and consolidation. X.X., C.W., D.M., G.L., Q.C., and N.J. participated in machine
learning analyses. T.C.H., X.X., and A.-L.L. participated in Pearson correlation and
statistical analyses. K.N., P.K.C., F.E., D.A.Z., and A.-L.L. participated in data verification
and result interpretation. T.C.H., X.X., C.W., D.M., K.N., P.K.C., F.E., D.A.Z., G.L., Q.C.,
L.M.Y., N.J., and A.-L.L. participated in manuscript writing.
Competing interests
The authors declare no competing interests.
Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s42003-
020-1079-x.
Correspondence and requests for materials should be addressed to A.-L.L.
Reprints and permission information is available at http://www.nature.com/reprints
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2020
COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-020-1079-x ARTICLE
COMMUNICATIONS BIOLOGY |           (2020) 3:352 | https://doi.org/10.1038/s42003-020-1079-x | www.nature.com/commsbio 13
